15-08-2013 дата публикации
Номер: US20130210911A1
Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine Dreceptor. The method comprises administering a composition comprising an effective amount of verapamil and a pharmaceutically acceptable excipient to a subject, wherein the verapamil is capable of binding to at least one of a receptor selected from the group consisting of orexin receptor 1, orexin receptor 2, somatostatin receptor 2 and dopamine Dreceptor of the subject. 1. A use of verapamil for the manufacture of a medicament for treating a disease or condition related to orexin receptor 1 , orexin receptor 2 , somatostatin receptor 2 or dopamine D , receptor , wherein the verapamil is capable of binding to any of the orexin receptor 1 , orexin receptor 2 , somatostatin receptor 2 or dopamine D , receptor.2. The use of claim 1 , wherein the verapamil is any of (R)-(+)-verapamil claim 1 , (S)-(−)-verapamil claim 1 , a mixture of (R)-(+)-verapamil and (S)-(−)-verapamil claim 1 , a pharmaceutically acceptable derivative claim 1 , stereoisomer claim 1 , metabolite claim 1 , salt or solvate thereof claim 1 , or a combination thereof.3. The use of claim 2 , wherein the verapamil is any of (R)-(+)-verapamil claim 2 , a pharmaceutically acceptable derivative claim 2 , stereoisomer claim 2 , metabolite claim 2 , salt claim 2 , or solvate thereof or a combination thereof.4. The use of claim 1 , wherein the disease or condition related to orexin receptor 1 or orexin receptor 2 is selected from the group consisting of obesity claim 1 , migraine claim 1 , cluster headache claim 1 , Parkinson's disease claim 1 , Alzheimer's disease claim 1 , depression claim 1 , addictions claim 1 , anxiety claim 1 , cancer claim 1 , diabetes claim 1 , insomnia claim 1 , irritable bowel syndrome claim 1 , narcolepsy claim 1 , neuropathic pain claim 1 , pain claim 1 , schizophrenia claim 1 , sleep disorder claim 1 , and Tourette ...
Подробнее